390815-40-4

Basic information

• Product Name: (R)-2-(3,4-dimethoxyphenyl)propanoic acid
• Synonyms: (R)-2-(3,4-dimethoxyphenyl)propanoic acid
• CAS NO: 390815-40-4
• Molecular Weight: 210.23
• Mol File: 390815-40-4.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (R)-2-(3,4-dimethoxyphenyl)propanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-(3,4-dimethoxyphenyl)propanoic acid(390815-40-4)
• EPA Substance Registry System: (R)-2-(3,4-dimethoxyphenyl)propanoic acid(390815-40-4)

Safety Data

• Hazardous Substances Data: 390815-40-4(Hazardous Substances Data)

Upstream product

• 1386351-11-6 (R)-2-(3,4-dimethoxyphenyl)-N-((R)-2-hydroxy-1-phenylethyl)propanamide 
• 138505-14-3 2-(3,4-dimethoxyphenyl)propanoic acid 
• 29207-02-1 methyl 2-(3,4-dimethoxyphenyl)propanoate 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 15964-79-1 methyl (3,4-dimethoxyphenyl)acetate 

Downstream Products

• 1386351-20-7 C₁₁H₁₆O₃ 
• 1386351-18-3 (R)-2-(3,4-dimethoxyphenyl)propionaldehyde 
• 1386350-40-8 (R)-2-(3,4-dimethoxyphenyl)-1-(5-methoxy-2,2-dimethyl-2H-chromen-6-yl)propan-1-one 

Relevant articles and documents

NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel compound inhibiting Hsp 90 and to a pharmaceutical composition including same as an active ingredient. Compounds of formula 1 and formula 2 according to the present invention inhibit the accumulation of HIF-1α protein, which is an Hsp90 client protein, by suppressing Hsp90 expression, and effectively inhibit the activity of vascular endothelial growth factor (VEGF). Furthermore, said compounds have low cytotoxicity and can thus be used as an active ingredient for the treatment of diabetic retinopathy and arthritis.

Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis

Deguelin exhibits potent apoptotic and antiangiogenic activities in a variety of transformed cells and cancer cells. Deguelin also exhibits potent tumor suppressive effects in xenograft tumor models for many human cancers. Our initial studies confirmed that deguelin disrupts ATP binding to HSP90 and consequently induces destabilization of its client proteins such as HIF-1α. Interestingly, a fluorescence probe assay revealed that deguelin and its analogues do not compete with ATP binding to the N-terminus of HSP90, unlike most HSP90 inhibitors. To determine the key parts of deguelin that contribute to its potent HSP90 inhibition, as well as its antiproliferative and antiangiogenic activities, we have established a structure-activity relationship (SAR) of deguelin. In the course of these studies, we identified a series of novel and potent HSP90 inhibitors. In particular, analogues 54 and 69, the B- and C-ring-truncated compounds, exhibited excellent antiproliferative activities with IC50 of 140 and 490 nM in the H1299 cell line, respectively, and antiangiogenic activities in zebrafish embryos in a dose dependent manner (0.25-1.25 μM).